突变与结直肠癌不良临床病理结局相关：一项荟萃分析。
mutation is associated with poor clinicopathological outcomes in colorectal cancer: A meta-analysis.
作者信息
Li Yujie, Li Weier
机构信息
Department of Surgical Oncology, Ningbo NO. 2 Hospital, Hangzhou, Zhejiang, China.
Department of Colorectal Surgery, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
出版信息
Saudi J Gastroenterol. 2017 May-Jun;23(3):144-149. doi: 10.4103/1319-3767.207712.
BACKGROUND/AIMS: The clinical relevance of the BRAF mutation in colorectal carcinoma (CRC) remains controversial. We performed a comprehensive meta-analysis to evaluate the precise relationship of BRAF mutation to clinicopathological features.
MATERIALS AND METHODS
A systematic search of the electronic databases, including PubMed, the Web of Knowledge, and the China Journal Net was performed between January 2005 and December 2015. Outcomes of interest included gender, tumor site, tumor differentiation, node involvement, tumor size, and AJCC stage. We calculated the pooled odds ratios (ORs) or risk ratios with 95% confidence intervals (CIs) for each study using a random or fixed-effect model.
RESULTS
Twenty-five studies with a total of 13208 patients were included. BRAF mutation-positive CRC patients were 1464 (11.1%). Our meta-analysis revealed that, in patients with CRC, the BRAF mutation was associated with female, proximal site, poor differentiation, >5 cm size, and advanced AJCC stage.
CONCLUSIONS
This meta-analysis demonstrated that BRAF mutation was closely related to adverse pathological features and poor outcome of CRC.
背景/目的：BRAF突变在结直肠癌（CRC）中的临床相关性仍存在争议。我们进行了一项全面的荟萃分析，以评估BRAF突变与临床病理特征之间的确切关系。
材料与方法
在2005年1月至2015年12月期间，对包括PubMed、Web of Knowledge和中国期刊网在内的电子数据库进行了系统检索。感兴趣的结果包括性别、肿瘤部位、肿瘤分化、淋巴结受累情况、肿瘤大小和美国癌症联合委员会（AJCC）分期。我们使用随机或固定效应模型计算每项研究的合并比值比（OR）或风险比以及95%置信区间（CI）。
结果
纳入了25项研究，共13208例患者。BRAF突变阳性的CRC患者有1464例（11.1%）。我们的荟萃分析显示，在CRC患者中，BRAF突变与女性、近端部位、低分化、>5 cm大小和晚期AJCC分期相关。
结论
这项荟萃分析表明，BRAF突变与CRC不良病理特征和不良预后密切相关。
Zotero 插件